Evaluation of neurofilament light chain levels in multiple sclerosis during acute attack periods

Alp Sarıteke; Levent Öcek; İnanç Karakoyun; Ayfer Çolak; Ufuk Şener

Makale detayları

Evaluation of neurofilament light chain levels in multiple sclerosis during acute attack periods

Yazarlar:

Alp Sarıteke | Levent Öcek | İnanç Karakoyun | Ayfer Çolak | Ufuk Şener

Yayıncı:

Cukurova University

Ana Başlıklar:

Nöroloji ve Nöromüsküler Hastalıklar

Dergi:

Cukurova Medical Journal Vol.49 Issue 4, pp.901-907

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001329042

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Purpose: The aim of this study is to evaluate how the serum neurofilament light chain sNfL was influenced in the multiple sclerosis MS patients before and after treatment of an acute attacks, and to determine the relationship of it with clinical findings. Materials and Methods: Thirty eight patients with a definite diagnosis of relapsing-remitting MS RRMS and who had a clinical acute attack between December 2019 and November 2020 were included in the study. The sNfL levels were studied before and after the treatment of an acute attacks. The relationship of sNfL levels with the patients clinical characteristics and treatment of acute attack was analyzed. Results: The sNfL levels of a total of 38 RRMS patients were evaluated. The mean age of the patients were 35.8  9.68 years 19-55 years. The sNfL level before and after treatment of acute attack were 3.55 pgmL 3.09-4.54 pgmL and 3.36 pgmL 3.01-3.86 pgmL, respectively. No statistically significant difference was found between the sNfL levels before and after treatment. Likewise, no relationship between the before and after treatment sNfL levels with clinical findings such as gender, age, duration of disease, and biochemical findings were detected. Conclusion: In our study, we found that the sNfL level, which is a biomarker of the prognosis and neuronal degeneration in the long-term, did not influenced by the high dose corticosteroid treatment.

 Purpose: The aim of this study is to evaluate how the serum neurofilament light chain sNfL was influenced in the multiple sclerosis MS patients before and after treatment of an acute attacks, and to determine the relationship of it with clinical findings. Materials and Methods: Thirty eight patients with a definite diagnosis of relapsing-remitting MS RRMS and who had a clinical acute attack between December 2019 and November 2020 were included in the study. The sNfL levels were studied before and after the treatment of an acute attacks. The relationship of sNfL levels with the patients clinical characteristics and treatment of acute attack was analyzed. Results: The sNfL levels of a total of 38 RRMS patients were evaluated. The mean age of the patients were 35.8  9.68 years 19-55 years. The sNfL level before and after treatment of acute attack were 3.55 pgmL 3.09-4.54 pgmL and 3.36 pgmL 3.01-3.86 pgmL, respectively. No statistically significant difference was found between the sNfL levels before and after treatment. Likewise, no relationship between the before and after treatment sNfL levels with clinical findings such as gender, age, duration of disease, and biochemical findings were detected. Conclusion: In our study, we found that the sNfL level, which is a biomarker of the prognosis and neuronal degeneration in the long-term, did not influenced by the high dose corticosteroid treatment.

 Purpose: The aim of this study is to evaluate how the serum neurofilament light chain sNfL was influenced in the multiple sclerosis MS patients before and after treatment of an acute attacks, and to determine the relationship of it with clinical findings. Materials and Methods: Thirty eight patients with a definite diagnosis of relapsing-remitting MS RRMS and who had a clinical acute attack between December 2019 and November 2020 were included in the study. The sNfL levels were studied before and after the treatment of an acute attacks. The relationship of sNfL levels with the patients clinical characteristics and treatment of acute attack was analyzed. Results: The sNfL levels of a total of 38 RRMS patients were evaluated. The mean age of the patients were 35.8  9.68 years 19-55 years. The sNfL level before and after treatment of acute attack were 3.55 pgmL 3.09-4.54 pgmL and 3.36 pgmL 3.01-3.86 pgmL, respectively. No statistically significant difference was found between the sNfL levels before and after treatment. Likewise, no relationship between the before and after treatment sNfL levels with clinical findings such as gender, age, duration of disease, and biochemical findings were detected. Conclusion: In our study, we found that the sNfL level, which is a biomarker of the prognosis and neuronal degeneration in the long-term, did not influenced by the high dose corticosteroid treatment.

 Amaç: Bu çalışmanın amacı, multipl skleroz MS hastalarında serum nörofilament hafif zincir sNfL düzeylerinin atak tedavisi öncesi ve sonrasında akut dönemde nasıl etkilendiğinin incelenmesi ve klinik bulgular ile ilişkisinin değerlendirilmektir. Gereç ve Yöntem: Aralık 2019-Kasım 2020 tarihleri arasında kesin olarak relapsing-remitting MS RRMS tanısı olan ve klinik atak geçiren 38 hasta çalışmaya dahil edildi. Hastaların demografik ve klinik verileri kayıt altına alındı. Atak öncesi ve tedavisi sonrasındaki sNfL düzeyleri çalışıldı. sNfL düzeylerinin hastaların klinik özellikleri ve atak tedavisi ile ilişkisi analiz edildi. Bulgular: Toplam 38 RRMS hastasını sNfL örnekleri değerlendirildi. Hastaların yaş ortalaması 35.8  9.68 yıl 19  55 yıl idi. Hastaların atak tedavi öncesinde ortanca sNfL düzeyi 3.55 pgmL 3.09  4.54 pgmL, sonrasında ise 3.36 pgmL 3.01  3.86 pgmL idi. Atak tedavisi öncesi ve sonrasındaki sNfL düzeyleri arasında istatistiksel olarak anlamlı fark saptanmadı. Atak tedavisi öncesi ve sonrasındaki sNfL düzeyleri ile hastaların cinsiyet, yaş, hastalık süresi gibi klinik bulgular ve laboratuvar bulguları arasında anlamlı ilişki gösterilemedi. Atak tedavisi sonrasında immünglobülin G indeksi yüksek olan grupta sNfL düzeyinin daha fazla azaldığı gösterildi, ancak istatistiksel anlamlık saptanmadı. Sonuç: Prognostik ve uzun dönemde nöronal dejenerasyon belirteci olan sNfLin yüksek doz kortikosteroid tedavisinden etkilenmediği çalışmamızda gösterilmiştir.

Makale detayları

Evaluation of neurofilament light chain levels in multiple sclerosis during acute attack periods

Yazarlar:

Alp Sarıteke | Levent Öcek | İnanç Karakoyun | Ayfer Çolak | Ufuk Şener

Yayıncı:

Cukurova University

Ana Başlıklar:

Nöroloji ve Nöromüsküler Hastalıklar

Dergi:

Cukurova Medical Journal Vol.49 Issue 4, pp.901-907

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001329042

pISSN:

2602-3032

Attack treatment

Corticosteroid

Multiple Sclerosis

Neurofilament

Neurofilament Light ChainAtak tedavisi

Kortikosteroid

Multipl skleroz

Nörofilament

Nörofilament hafif zincir

Sayı

Makale detayları

Yazarlar: Alp Sarıteke | Levent Öcek | İnanç Karakoyun | Ayfer Çolak | Ufuk Şener

Yayıncı: Cukurova University

Ana Başlıklar: Nöroloji ve Nöromüsküler Hastalıklar

Dergi: Cukurova Medical Journal Vol.49 Issue 4, pp.901-907

Belge Tipi: Makale

Yayın Tarihi: 12/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001329042

pISSN: 2602-3032

Sayı

Yazarlar:

Alp Sarıteke | Levent Öcek | İnanç Karakoyun | Ayfer Çolak | Ufuk Şener

Yayıncı:

Cukurova University

Ana Başlıklar:

Nöroloji ve Nöromüsküler Hastalıklar

Dergi:

Cukurova Medical Journal Vol.49 Issue 4, pp.901-907

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001329042

pISSN:

2602-3032